New therapies: Plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies

Critical Care Clinics

Volumn 18, Issue 4, 2002, Pages 957-975

  Saydain, Ghulam ^a   George, Liziamma ^a   Raoof, Suhail ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CDP571; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CATHETER ABLATION; CLINICAL TRIAL; DERMATOMYOSITIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOADSORPTION; IMMUNOTHERAPY; INJECTION PAIN; MYASTHENIA GRAVIS; NONHUMAN; PATIENT MONITORING; PLASMAPHERESIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSORBENT TECHNIQUES; PLASMAPHERESIS; RHEUMATIC DISEASES;

EID: 0036839536     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(02)00028-3     Document Type: Review

References (152)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
3. Strand V. Monoclonal antibodies and other biologic therapies. Lupus 2001;10:216-21.
4. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977;297:1386-9.
5. Schneider KM. Plasmapheresis and immunoadsorption: Different techniques and their current role in medical therapy. Kidney Int 1998;53:s61-65.
6. Shumark KH, Rock GA. Therapeutic plasma exchange. N Engl J Med 1984;310:762-71.
7. Tesar V, Jelinkova E, Masek Z, et al. Influence of plasma exchange on serum levels of cytokines and adhesion molecules in ANCA-positive renal vasculitis. Blood Purif 1998;16:72-80.
8. Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000;59:77-80.
9. Entanercept. http://www.fda.gov/cber/label/cntanimm10019918.pdf.
10. Go RS, Call TG. Deep venous thrombosis of the arm after immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000;75:83-5.
11. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
12. Levy JB, Pusey CD. Nephrotoxicity of immunoglobulin. QJM 2000;93:751-5.
13. McLeod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999;39:282-8.
14. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994;121:259-62.
15. Sherer Y, Levy Y, Langevitz P, et al. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001;62(3):133-7.
16. Valbunesi M, Bruni R, De Luigi MC. Therapeutic hemapheresis as of 2000. Vox Sang 2000;78(Suppl 2):51-6.
17. McLeod B. Introduction to the third special issue: Clinical application of therapeutic apheresis. J Clin Apheresis 2000;15:1-5.
18. Lockwood CM, Worlledge S, Nicholas A, et al. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979;300:524-30.
19. Low A, Hotze A, Krapf F, et al. The non-specific clearance function of the reticuloendothelial system in patients with immune complex mediated disease before and after therapeutic plasmapheresis. Rheumatol Int 1985;5:69-72.
20. Dau PC. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. J Neuroimmunol 1990;30:15-21.
21. Hanly JG, Hong C, Zayed E, Jones J, et al. Immunomodulating effects of synchronized plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 1995;4(6):457-63.
22. Council on Scientific Affairs. Current status of therapeutic plasmapheresis and related techniques. JAMA 1985;253:819-24.
23. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: An update from the Canadian Apheresis Group. Ann Intern Med 1999;131:453-62.
24. Leitman SF, Kucera E, McLeod B, et al. Guidelines for Therapeutic Hemapheresis. Bethesda (MD): American Association of Blood Banks; 1992
25. Strauss RG, Ciavarella D, Gilcher RO, et al. An overview of current management. J Clin Apheresis 1993;8:189-94.
26. Karsh J, Klippel JH, Plotz PH, et al. Lymphapheresis in rheumatoid arthritis. A randomized trial. Arthritis Rheum 1981;24:867-73.
27. Wallace D, Goldfinger D, Lowe C, et al. A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. N Engl J Med 1982;306:1406-10.
28. Wallace DJ, Goldfinger D, Gatti R, et al. Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. Arthritis Rheum 1979;22:703-10.
29. Dwosh IL, Giles AR, Ford PM, et al. Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial. N Engl J Med 1983;308:1124-9.
30. Rothwell RS, Davis P, Gordon PA, et al. A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis Rheum 198;23:785-90.
31. Verdickt W, Dequeker J, Ceuppens JL, et al. Effects of lymphoplasmapheresis on clinical indices and T cell subsets in rheumatoid arthritis. A double blind controlled study. Arthritis Rheum 1983;26:1419-26.
32. Baron M, Fam AG, Elkan I, et al. Hyperviscosity sydrome in rheumatoid arthritis. J Rheumatol 1982;9:843-9.
33. Eaton AM, Serota H, Kernodle Jr. GW, et al. Pulmonary hypertension secondary to serum hyperviscosity in patients with rheumatoid arthritis. Am J Med 1987;82:1039-45.
34. Goldman JA, Casey HL, McIlwain H, et al. Limited plasmapheresis in rheumatoid arthritis with vasculitis. Arthritis Rheum 1979;22:1146-50.
35. Panush RS, Katz P, Longley S, et al. Rheumatoid vasculitis: Diagnostic and therapeutic decisions. Clin Rheumatol 1983;2:321-30.
36. Schneider HA, Yonker RA, Katz P, et al. Rheumatoid vasculitis: Experience with 13 patients and review of the literature. Semin Arthritis Rheum 1985;14:280-6.
37. Scofield RH, Tardibono G, Ogden SB, et al. Rheumatoid hyperviscosity: Analysis of a patient with intermediate complexes that block other autoantibodies and a review of the literature. Semin Arthritis Rheum 1998;27:382-91.
38. Scott DGI, Bacon PA, Bothamley JE, et al. Plasma exchange in rheumatoid vasculitis. J Rheumatol 1981;8:433-9.
39. Winkelstein A, Starz TW, Agarwal A. Efficacy of combined therapy with plasmapheresis and immunosuppressants in rheumatoid vasculitis. J Rhuematol 1984;11:162-6.
40. Euler HH, Schroeder JO, Harten P, et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37:1784-94.
41. Jones JV, Bucknall RC, Cumming RH, et al. Plasmapheresis in the management of acute systemic lupus erythematosus. Lancet 1976;1:709-11.
42. Wei N, Huston DP, Lawley TJ, et al. Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1983;I:17-21.
43. Campion EW. Desperate diseases and plasmapheresis. N Engl J Med 1992;326:1425-7.
44. Lewis EJ, Hunsicker LG, Lan SP, et al for the Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe nephritis. N Engl J Med 1992;326:1373-9.
45. Wallace DJ, Goldfinger D, Pepkowitz SH, et al. Randomized control trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis 1998;13:163-6.
46. Khamashta MA, Cervera R, Hughes GR. The central nervous system in systemic lupus erythematosus. Rheumatol Int 1991;11:117-9.
47. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception cohort. Arthritis Rheum 1995;38(10):1492-9.
48. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996;156(12):1337-44.
49. Zamora MR, Warner ML, Tuder R, et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival and outcome. Medicine (Baltimore) 1997;76:192-202.
50. Wallace D. Apheresis for lupus erythematosus: State of the art. Lupus 2001;10:193-96.
51. Erickson RW, Franklin WA, Emlin W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994;24:114-23.
52. Huang DF, Tsai ST, Wang SR. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patients with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfusion Sciences 1994;15:283-8.
53. Santos-Ocampo AS, Mandel BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus. Presentation and management. Chest 2000;118:1083-90.
54. Evans DT, Giles M, Home DJ, et al. Cerebral lupus erythematosus responding to plasmapheresis. Postgrad Med J 1981;57:247-51.
55. Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus. Am J Med 1995;98:32-41.
56. Navarrete MG, Brey RL. Neuropsychiatric systemic lupus erythematosus. Current Treatment Options in Neurology 2000;2:473-85.
57. Matsumoto Y, Naniwa D, Banno S, et al. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: Two case reports. Ther Apher 1998;2:300-4.
58. Takeshita Y, Turumi Y, Touma S, et al. Successful delivery in a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus treated with double filtration plasmapheresis. Ther Apher 2001;5:22-4.
59. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid antibody syndrome. Clinical and laboratory feature of 50 patients. Medicine (Baltimore) 1998;77:195-207.
60. Asherson RA. The catastrophic antiphospholipid antibody syndrome, 1998. A review of clinical features, possible pathogenesis and treatment. Lupus 1998;7(suppl 2):S55-62.
61. Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Straus syndrome: A prospective, randomized trial in 78 patients. Arthritis Rheum 1992;35:208-15.
62. Pusey CD, Rees AJ, Evans DJ, et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757-63.
63. Dau PC. Plasmapheresis in idiopathic inflammatory myopathy: Experience with 35 patients. Arch Neurol 1981;38:544-52.
64. Cherin P, Auperin I, Bussel A, et al. Plasma exchange in polymyositis and dermatomyositis: A multicenter study of 57 cases. Clin Exp Rheumatol 1995;13:270-1.
65. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-4.
66. Weiner SR, Kono DH, Osterman HA. Preliminary report on a controlled trial of apheresis in the treatment of scleroderma. Arthritis Rheum 1987;30:s24.
67. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy: Results of a multicenter trial. Arch Dermatol 1992;128:337-46.
68. McCune MA, Winkelmann RK, Osmundson PJ, et al. Plasma exchange: A controlled study of the effects in patents with Raynaud's phenomenon and scleroderma. J Clin Apheresis 1983;1:206-14.
69. Talpos G, Horrocks M, White JM, et al. Plasmapheresis in Raynaud's disease. Lancet 1979;1:416-7.
70. Dodds EM, Lowder CY, Foster RE. Plasmapheresis treatment of central retinal vein occlusion in a young adult. Am J Ophthalmol 1995;119(4):519-21.
71. Flechtner KM, Baum K. Mixed connective disease: Recurrent episodes of optic neuropathy and transverse myelopathy. Succesful treatment with plasmapheresis. J Neurol Sci 1994;126:146-8.
72. Seguchi M, Soejima Y, Tateishi A, et al. Mixed connective tissue disease with multiple organ damage: Successful treatment with plasmapheresis. Intern Med 2000;39(12):1119-22.
73. Langone JJ. Protein A of Staphylococcus and related immunoglobulin receptors produced by streptococci and pneumococci. Adv Immunol 1982;32:157-252.
74. Felson DT, LaValley MP, Baldassare AR, et al. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized double blind sham-controlled trial. Arthritis Rheum 1999;42:2153-9.
75. Felson DT, Anderson JJ, Boeres M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
76. Furst D, Felson D, Thoren G, et al. Immunoadsorption for the treatment of rheumatoid arthritis: Final results of a randomized trial. Prosorba Trial Investigators. Ther Apher 2000;4:363-73.
77. Funauchi M, Ikoma S, Imada A, et al. Combination of immunoadsorption therapy and high dose methylprednisone in patients with lupus nephritis; possible indication in patients with early stage. J Clin Lab Immunol 1997;49:47-57.
78. Gaubitz M, Seidel M, Kummer S, et al. Prospective randomized trial of two different immunoabsorbers in severe systemic lupus erythematosus. J Autoimmun 1998;11:495-501.
79. Pfueller B, Wolbart K, Bruns A, et al. Successful reatment of patients with systemic lupus erythematosus by immunoadsorption with C1q column: A pilot study. Arthritis Rheum 2001;4:1962-3.
80. Nakamura Y, Yoshida K, Itoh S, et al. Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. Am J Reprod Immunol 1999;41:307-11.
81. Matic G, Michelsen A, Hofmann D, et al. Three cases of c-ANCA-positive vasculitis treated with immunoadsorption: Possible benefit in early treatment. Ther Apher 2001;5(1):68-72.
82. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. N Engl J Med 2001;345:747-55.
83. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325(2):110-7.
84. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanism of action of intravenous immunoglobulin in immune-mediated diseases. Clin Exp Immunol 1996;104(Suppl 1):3-9.
85. Samuelsson A, Towers TL, Ravetch JV. Antiinflammatory activity of IVIG mediated through the inhibitory FC receptor. Science 2001;291:484-6
86. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody mediated diseases. N Engl J Med 1999;340:227-8.
87. Van der Meche FG, Schmitz PI. Dutch Guillain-Barre Study Group. A randomized controlled trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123-9.
88. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. Engl J Med 1993;329:1993-2000.
89. Gajdos P, Shevret S, Clair B, et al for the Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-96.
90. Boletis JN, Ioannidis JP, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 999;354(9178):569-70.
91. Hundt M, Manger K, Dorner T, et al. Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology 2000;39:1301-2.
92. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992;10:391-3.
93. Arahata H, Migita K, Izumoto HH, et al. Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulin. Clin Rheumatol 1999;18:77-81.
94. Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000;29(5):321-7.
95. Sherer Y, Levy Y, Langevitz P, et al. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999;18:170-3.
96. Sherer Y, Levy Y, Shoenfeld Y, et al. Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 1999;18:238-40.
97. Kaaja R, Julkunen H, Ammala P, et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993;72:63-6.
98. Jayne DR, Davies MJ, Fox CJ, et al.. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991;337:1137-9.
99. Brox AG, Cournoyer D, Sternbach M, et al. Hemolytic anemia following intravenous hemoglobulin administration. Am J Med 1987;82:633-5.
100. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995;25:228-34.
101. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355:735-40.
102. Glennie MJ, Johnson PWM. Clinical trials of antibody therapy. Immunol Today 2000;20:403-10.
103. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
104. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
105. Lipsky PE, Van Der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti Tumour Necrosis Factor Trial on Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
106. Shergy W, Isem R, Cooley D, et al. Infliximab (Remicade ®) ameliorates clinical signs and symptoms of rheumatoid arthritis within 48 hours. Results of PROMPT study [abstract]. Arthritis Rheum 2001;43(Suppl):s227.
107. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumour necrosis factor alpha: Findings in open-label and randomized placebocontrolled trials. Arthritis Rheum 2000;43:2383-90.
108. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
109. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
110. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
111. Keystone EC. Tumour necrosis factor-α blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:427-43.
112. Klippel JH. Biologic therapy for rheumatoid arthritis. N Engl J Med 2000;343:1640-1.
113. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
114. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999;131:634.
115. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
116. Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human antitumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
117. Rau R, Herborin G, Sander O, et al. Long-term treatment with the fully humanized anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritis Rheum 1999;42(Suppl):S400.
118. Van de Putte LBA, Rau R, Breedveld FC, et al. Effficacy of fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum 1992;42:S400.
119. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
120. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
121. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol 1993;20:259-62.
122. Choy EH, Isenberg DA, Farrow S, et al. A double blind randomized placebo controlled trial of anti interleukin 6 (1L-6) receptor antibody in rheumatoid arthritis. Arthritis Rheum 2001;44(suppl):S274.
123. Yoshizaki K, Nishimoto N, Mihara M, et al. Theraphy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998;20:247-59.
124. Moreland LW, Pratt PW, Mayes MD, et al. Double-blind placebo-controlled multicenter trial using monoclonaI anti-CD4 antibody cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581-8.
125. Van den Bosch F, Russell A, Keystone EC, et al. rHUIL-4 in subjects with active rheumatoid arthritis (RA): A phase I dose escalating safety study. Arthritis Rheum 1998;41(Suppl):S56.
126. Moreland LW. Potential biologic agents for treating rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:445-91.
127. Ishida H, Muchamuel T, Sakaguchi S, et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
128. Park Y, Lee SK, Kim DS, et al. Elevated levels of interleukin-10 correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8.
129. Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effect of anti-interleukin-10 monoclonal antibody administered in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
130. Foy TM, Aruffo A, Bajorath J, et al. Immune regulation by CD40 and its ligand of p39. Ann Rev Immunol 1996;14:591-617.
131. Grammer AC, Bergman MC, Miura Y, et al. The CD40 ligand expressed by human B cells co-stimulates B cell responses. J Immunol 1995;154:4996-5010.
132. Kato K, Santana-Sahagun E, Rassenti LZ, et al. Elevated soluble CD40-ligand (CD154) in plasma of patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:S71.
133. Kalled SL, Cutler AH, Datta SK, et al. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: Preservation of kidney function. J Immunol 1998;160:2158-65.
134. Mohan C, Shi Y, Laman JD, et al. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-80.
135. Boumpas DT, Furie RA, Manzi S, et al. A short course of BG9588 (anti-CD40L antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2001;44(suppl):S387
136. Davis Jr. JC, Totoritis MC, Rosenberg J, et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001;28:95-101.
137. Kalunian K, Davis J, Merill JT, et al. Treatment of SLE by inhibition of T cell costimulation. Arthritis Rheum 2000;43:S271.
138. Wallace DJ. Clinical and pharmacological experience with LJP-394. Expert Opinion on Investigational Drugs 2001;10(1):111-7.
139. Jones DS, Barstad PA, Feild MJ, et al. Immunospecific reduction of anti-oligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995;38(9):2138-44.
140. Furie RA, Cash JM, Cronin ME, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-65.
141. Weisman MH, Bluestein HG, Berner CM, et al. Reduction in circulating dsDNA antibody titer after administration of LJP-394. J Rheumatol 1997;24:314-8.
142. Alarcon-Segovia D, Tumlin J, Furie R, et al. SLE trial shows fewer renal flares in LJP-394 treated patients with high affinity antibodies to LJP 394: 90-05 Trial results. Arthritis Rheum 2000;43:S272.
143. Linnik MD, Bagin RG. Effect of LJP 394 on patients with greatest impairment of renal function at the baseline in the 90-05 trial. Arthritis Rheum 2000;43:S241.
144. Daikh DI, Finck BK, Linsley PS, et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159:3104-8.
145. Spertini F, Leimgruber A, Morel B, et al. Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with non active systemic lupus erythematosus with nephritis. J Rheumatol 1999;26:2602-8.
146. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33(17-18):1389-401.
147. Marmont AM. Immune ablation with stem-cell rescue: A possible cure for systemic lupus erythematosus? Lupus 1993;2:151-6.
148. Burt RK, Slavin S, Burns WH, et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure? Blood 2002;99:768-84.
149. Traynor AE, Schroeder J, Rosa RM. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study. Lancet 2000;356(9231):701-7.
150. Evans CH, Ghivizzani SC, Oligino TJ, et al. Gene therapy for autoimmune disorders. J Clin Immunol 2000;20(5):334-46.
151. Ghivizzani SC, et al. Results of the first human clinical trial of gene therapy for arthritis. Arthritis Rheum 1999;42(Suppl):171, 1999.
152. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.